Randomised, open-label study of inhaled sargramostim (recombinant human GM-CSF) in hospitalised COVID-19 patients meets primary endpoint

In the SARPAC study in patients requiring supplemental oxygen (n=81), inhaled sargramostim met the primary endpoint of improved oxygenation after 5 days of treatment compared with standard of care alone, with improvement of ≥33% in 54% versus 26%, respectively (p=0.0147).

Source:

Biospace Inc.